Following Pfizer, the U.S. Food and Drug Administration also approved the use of MSD as a treatment. However, due to the potential for serious side effects, only limited use was allowed.
Correspondent Yunsu Kim from Washington.
The U.S. Food and Drug Administration (FDA) announced that it has approved the use of molnupiravir, a COVID-19 pill treatment developed by MSD.
Yesterday (23rd), after Pfizer’s ‘Pax Lovid’, the second Corona 19 treatment pill was approved.
However, MSD treatment was found to be significantly less effective than Pfizer treatment.
The rate of lowering hospitalization and mortality in high-risk patients is about 30%, which is one-third that of Pfizer’s treatment.
In addition, it is reported that there is a possibility of serious side effects such as birth defects.
The FDA has warned that both men and women should use birth control for a period of time after taking the drug, and has banned its use in patients under the age of 18 because it may affect growth.
It was only approved for use in high-risk groups, etc., when there was no other treatment alternative.
Previously, Pfizer’s treatment, approved for high-risk patients 12 years of age and older, reported only relatively mild side effects, such as decreased taste, diarrhea, and high blood pressure.
The White House announced that it has secured 10 million doses of Pfizer treatment and will supply 260,000 doses in January next year.
[제프 자이언츠/백악관 코로나19 대응 조정관 : 화이자사가 코로나 치료제를 제조해 납품하는 대로 저희는 미 전역에 공급할 예정입니다.]
Pfizer drugs are known to take about nine months to manufacture, so competition around the world is expected to intensify for securing initial supply.